Dr Dimitra Mitsa

Dr Dimitra Mitsa

Profile

I joined the University of Leeds in July 2022 as a Lecturer in Biotechnology (Teaching & Scholarship pathway) as part of the Curriculum Redefined strategic initiative.

Prior to my employment at the university, I worked for more than a decade in the biopharmaceutical sector (GlaxoSmithKline, MedImmune-Astrazeneca, Intertek, Ipsen Biopharm) specialising in analytical and biophysical techniques for biopharmaceutical characterisation, with particular focus in biomolecular mass spectrometry.

In addition to my work in industry, I spent two years as a postdoctoral research associate at the University of Liverpool, MRC Centre for Drug Safety Science, investigating drug induced changes in the hepatic proteome.

I decided to return to academia and utilise my knowledge and expertise to teach the future generation of scientists, after lecturing online, part-time, for the Atlantic Technological University in Ireland.

Awards

  • Advance HE CATE Team Lead and Award Holder, 2025
  • Sustained Collaborative Excellence Award, Univerity of Leeds, 2024

Responsibilities

  • Programme Leader
  • Module Manager

Research interests

My scholarly work involves developing industry-informed curiculla with an emphasis on internationalisation, employability, and digitally enhanced teaching. I am also interested in exploring topics that lie at the dynamic intersection of biotechnology, law and ethics.

Qualifications

  • PhD Biophysical Chemistry (University of Edinburgh)
  • BSc Molecular Microbiology (University of Surrey)
  • BSc Marketing (University of LaVerne)
  • LLM (University of London)
  • PGCAP (University of Leeds)

Professional memberships

  • Advance HE Fellow (FHEA)

Student education

Programme Leader for the following programmes:

  • MSc. Biopharmaceutical Development (2022-Present)
  • MSc. Biopharmaceutical Development with Industrial Placement (2022-Present)
  • MSc. Bioscience (2022-2024)
  • MSc. Plant Science & Biotechnology (2022-2024)

Module Manager:

  • BIOL5181M Manufacturing Biopharmaceuticals (2022-Present)